  Purpose To evaluate a single institution 's experience with granulocyte colony-stimulating factor after autologous hematopoietic stem cell transplant in myeloma patients to identify populations that benefit most from granulocyte colony-stimulating factor administration. Methods Retrospective chart reviews were conducted on patients 18 + years with multiple myeloma that underwent autologous hematopoietic stem cell transplant at UW Health from January 2012 to May 2016. Data collection included demographics , length of stay , time to engraftment , Eastern Cooperative Oncology Group performance status score , and hematopoietic cell transplantation-comorbidity index. The primary outcome was days from transplant to engraftment , defined as absolute neutrophil count > 500/mm